Geron Corporation (NASDAQ: GERN) shares climbed 21% on news that the second internal data reviews of the company’s IMerge and IMbark clinical trials have been completed by Janssen Research & Development, LLC. IMerge, the study of the telomerase inhibitor imetelstat in lower risk myelodysplastic syndromes (MDS), demonstrated that the benefit/risk profile of imetelstat in the treated patients supports continued development. The company intends to provide the FDA with a data package and proposed trial design refinements. For IMbark, a study of imetelstat in relapsed or refractory myelofibrosis (MF), current data suggest clinical benefit and a potential overall survival benefit. The trial will continue unchanged to evaluate maturing efficacy and safety data, including an assessment of overall survival.
To view the full press release, visit: http://nnw.fm/cg8zT
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about the company, visit www.geron.com
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer